Cargando…

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial

AIMS: Therapy with i.v. iron in patients with chronic heart failure (CHF) and iron deficiency (ID) improves symptoms, functional capacity, and quality of life. We sought to investigate whether these beneficial outcomes are independent of anaemia. METHODS AND RESULTS: FAIR-HF randomized 459 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippatos, Gerasimos, Farmakis, Dimitrios, Colet, Josep Comin, Dickstein, Kenneth, Lüscher, Thomas F., Willenheimer, Ronnie, Parissis, John, Gaudesius, Giedrius, Mori, Claudio, von Eisenhart Rothe, Barbara, Greenlaw, Nicola, Ford, Ian, Ponikowski, Piotr, Anker, Stefan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Comorbidity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806282/ https://www.ncbi.nlm.nih.gov/pubmed/23787722 http://dx.doi.org/10.1093/eurjhf/hft099

Ejemplares similares

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
por: Comin-Colet, Josep, et al.
Publicado: (2013)

Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy
por: Okonko, Darlington O., et al.
Publicado: (2019)

Rationale and design of Ferinject(®) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
por: Anker, Stefan D., et al.
Publicado: (2009)

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Urinary peptides in heart failure: a link to molecular pathophysiology
por: He, Tianlin, et al.
Publicado: (2021)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK
por: Gutzwiller, Florian S., et al.
Publicado: (2012)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
por: Jankowska, Ewa A, et al.
Publicado: (2011)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies
por: Mugii, Naoki, et al.
Publicado: (2018)

Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity
por: Biskup, Małgorzata, et al.
Publicado: (2018)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
por: Traianos, Emmanuella Young, et al.
Publicado: (2020)

Self-reported fatigue in patients with rheumatoid arthritis compared to patients with cancer: results from two large-scale studies
por: Müller, Karolina, et al.
Publicado: (2021)

The association between type 2 diabetes and anhedonic subtype of major depression in hypertensive individuals
por: Willame, Hadrien, et al.
Publicado: (2022)

Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications
por: Kloner, Robert A., et al.
Publicado: (2022)

Tadalafil in patients on antihypertensive medications: Does safety remain an issue?
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction
por: Martens, Pieter
Publicado: (2022)

The Impact of Frailty and Comorbidities on Heart Failure Outcomes
por: Salmon, Thomas, et al.
Publicado: (2022)

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis
por: van den Oever, I. A. M., et al.
Publicado: (2020)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Evolution of tricuspid regurgitation after transcatheter edge‐to‐edge mitral valve repair for secondary mitral regurgitation and its impact on mortality
por: Adamo, Marianna, et al.
Publicado: (2022)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_60952qcb0n891u6tmg3caajp4c